Asset Details
Do you wish to reserve the book?
Ionized Calcium Binding Adaptor Molecule 1 (IBA1): A Novel, Highly Sensitive, and Specific Marker for Histiocytic, Dendritic, and Monocytic Neoplasms
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ionized Calcium Binding Adaptor Molecule 1 (IBA1): A Novel, Highly Sensitive, and Specific Marker for Histiocytic, Dendritic, and Monocytic Neoplasms
Do you wish to request the book?
Ionized Calcium Binding Adaptor Molecule 1 (IBA1): A Novel, Highly Sensitive, and Specific Marker for Histiocytic, Dendritic, and Monocytic Neoplasms
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ionized Calcium Binding Adaptor Molecule 1 (IBA1): A Novel, Highly Sensitive, and Specific Marker for Histiocytic, Dendritic, and Monocytic Neoplasms
2021
Overview
Ionized calcium binding adaptor molecule 1 (IBA1), a marker of microglia/macrophages, has not been investigated in human hematopathologic contexts. We evaluated its expression in mature and immature neoplasms of monocytic/histiocytic and dendritic cell (DC) origin.
Immunohistochemistry for IBA1, CD14, CD68, and CD163 was performed on a total of 114 cases, including a spectrum of monocytic/histiocytic and DC neoplasms (20 tissue based and 59 bone marrow based) and several nonhistiocytic/monocytic/DC neoplasms as control groups (15 tissue based and 20 bone marrow based).
IBA1 expression was observed in all types of mature tissue-based histiocytic/DC neoplasms (20/20) but not in the corresponding control group (0/15). In bone marrow-based cases, IBA1 was expressed in most acute myeloid leukemias (AMLs) with monocytic differentiation (48/53), both blastic plasmacytoid dendritic cell neoplasms (2/2), and all chronic myelomonocytic leukemias (4/4), while it was positive in only one nonmonocytic AML (1/15) and none of the acute lymphoblastic leukemias (0/5). Collectively, IBA1 showed much higher sensitivity and specificity (93.7%, 97.1%) compared with CD14 (65.4%, 88.2%), CD68 (74.4%, 74.2%), and CD163 (52.6%, 90.6%).
IBA1 is a novel, highly sensitive, and specific marker for diagnosing neoplasms of monocytic/histiocytic and DC origin.
Publisher
Oxford University Press
Subject
